Naarden, The Netherlands, 22 April 2021. –   BioGeneration Ventures (BGV), together with i2020, an accelerator program backed by the San Diego-based venture company Torrey Pines Investment, and OrbiMed have announced a new startup investment in Brenig Therapeutics, a start-up company focused on neurodegenerative disorders.  The company is part of the Loch Platform of companies which rationally designs and develops novel targeted treatments for cancer, immunological and neurodegenerative diseases. With this investment BGV, is joining i2020 and Orbimed as partner for the European science based ventures.

    The new investment from BGV, i2020 and OrbiMed, exemplifies opportunities in Europe to identify novel scientific discoveries and to use those in building innovative new companies to develop novel treatments for the benefit of patients.

    Managing Partner at BGV Edward van Wezel has been appointed to the Board of Directors of Brenig Therapeutics. “This latest investment personifies our approach at BGV,” stated Mr. van Wezel.  “Partnering our European expertise of developing projects from discovery to clinical proof-of-concept with strong American investors like Torrey Pines and OrbiMed sets the example for future trans-Atlantic partnerships of this nature, and underscores the potential of European science ”.

    The Loch platform and its programs are supported by the artificial intelligence and computer aided drug design and other research partners from i2020 Accelerator’s global network.

    Click here for the official press release.

     

    For Further Information:

    BGV

    E: info@biogeneration.vc
    T: +31 (0) 35 699 30 00